Toronto Dominion Bank increased its position in shares of Celgene Co. (NASDAQ:CELG) by 9.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 511,361 shares of the biopharmaceutical company’s stock after purchasing an additional 42,835 shares during the quarter. Toronto Dominion Bank owned 0.06% of Celgene worth $53,365,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in CELG. Janus Henderson Group PLC lifted its stake in Celgene by 4,290.5% during the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after purchasing an additional 8,217,433 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Celgene by 1,489.2% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after purchasing an additional 1,787,052 shares during the last quarter. Vanguard Group Inc. lifted its stake in Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares during the last quarter. Jennison Associates LLC lifted its stake in Celgene by 11.5% during the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after purchasing an additional 1,546,673 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Celgene by 785.9% in the second quarter. Renaissance Technologies LLC now owns 1,170,638 shares of the biopharmaceutical company’s stock valued at $152,031,000 after buying an additional 1,038,500 shares during the last quarter. Hedge funds and other institutional investors own 78.60% of the company’s stock.
A number of equities research analysts have issued reports on CELG shares. Cantor Fitzgerald set a $112.00 target price on Celgene and gave the company a “hold” rating in a research note on Wednesday, January 17th. William Blair reiterated a “buy” rating on shares of Celgene in a research note on Wednesday, February 28th. BMO Capital Markets reiterated a “buy” rating and issued a $147.00 target price on shares of Celgene in a research note on Friday, December 22nd. Credit Suisse Group set a $129.00 target price on Celgene and gave the company a “buy” rating in a research note on Thursday, March 1st. Finally, Stifel Nicolaus set a $130.00 target price on Celgene and gave the company a “buy” rating in a research note on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. Celgene currently has a consensus rating of “Buy” and an average target price of $127.78.
In related news, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $95.99, for a total transaction of $887,907.50. Following the transaction, the director now directly owns 94,801 shares of the company’s stock, valued at $9,099,947.99. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ernest Mario sold 13,370 shares of Celgene stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $94.49, for a total value of $1,263,331.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,120 shares of company stock worth $3,879,509. 0.95% of the stock is owned by corporate insiders.
CELG stock opened at $84.98 on Friday. The stock has a market capitalization of $65,371.59, a PE ratio of 23.74, a P/E/G ratio of 0.61 and a beta of 1.58. Celgene Co. has a fifty-two week low of $84.95 and a fifty-two week high of $147.17. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. The firm had revenue of $3.48 billion for the quarter, compared to analyst estimates of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. Celgene’s revenue was up 16.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.61 earnings per share. analysts anticipate that Celgene Co. will post 7.66 EPS for the current year.
Celgene declared that its board has initiated a share repurchase program on Wednesday, February 14th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
ILLEGAL ACTIVITY WARNING: This news story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/03/24/celgene-co-celg-shares-bought-by-toronto-dominion-bank.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.